Catalent and Phathom Pharmaceuticals strike commercial supply agreement
The CDMO will provide commercial manufacturing and packaging services for Phathom's novel, orally active P-CAB
Phathom Pharmaceuticals, a late clinical-stage biopharmaceutical company focused on developing and commercialising novel treatments for gastrointestinal disease, has secured Catalent's agreement for the commercial supply of its lead compound, vonoprazan.
Phathom's lead compound, which is currently in late clinical-stage development for the treatment of gastric acid-related diseases and disorders, is a novel, orally active potassium-competitive acid blocker (P-CAB). P-CABs are a new class of medicines that block acid secretion in the stomach.
Should vonoprazan receive FDA approval, Catalent will provide the commercial manufacturing and packaging of the product at its premier site for complex oral drug formulation and large-scale oral solid dose manufacturing in Winchester, Kentucky.
In 2015, the CDMO doubled the site's footprint to 180,000 sq. ft, and in 2019 undertook a $40-million investment that saw the installation of new equipment to increase its tablet and capsule manufacturing capabilities.
Dr Aris Gennadios, President, Softgel & Oral Technologies, Catalent described the agreement between the two companies as "the start of long-term partnership".
Phathom has the rights for the development and commercialization of vonoprazan in the US, Europe, and Canada.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.